Loading blog post…
A complete guide to rosacea — the four subtypes, the Demodex mite connection, the KLK5/LL-37 cathelicidin pathway, the vascular and neurovascular mechanisms, the evidence for topical and oral treatments, how to identify and manage triggers, and what to expect from laser and IPL procedures.
· By MedSpot Editorial · 6 min read
Rosacea is a chronic inflammatory condition of the facial skin affecting approximately 5–10% of the global population — most commonly in individuals with Fitzpatrick skin types I–III, though it occurs across all skin tones. It is frequently mismanaged as a cosmetic issue rather than a medical condition with defined pathophysiology and specific treatments. Here is the complete evidence-based guide.
The National Rosacea Society (NRS) classifies rosacea into four subtypes that often co-occur:
Subtype 1: Erythematotelangiectatic rosacea (ETR)
Subtype 2: Papulopustular rosacea (PPR)
Subtype 3: Phymatous rosacea
Subtype 4: Ocular rosacea
Demodex folliculorum and Demodex brevis are microscopic mites (hair follicle mites) that inhabit the pilosebaceous unit of virtually all humans — but are found at significantly higher densities on rosacea-affected skin compared to normal controls.
The mechanism: Demodex mites host the gram-negative bacterium Bacillus oleronius in their gut. When mites die and decompose in the follicle, bacterial proteins are released → trigger a pattern recognition receptor (TLR-2)-mediated innate immune response → produces cathelicidin (LL-37) and other antimicrobial peptides → drives the inflammatory cascade.
Evidence for Demodex's central role: ivermectin cream 1% (Soolantra) — an antiparasitic that kills Demodex mites — is FDA-approved for papulopustular rosacea and demonstrates superior efficacy to metronidazole in head-to-head RCTs.
Kallikrein-5 (KLK5) is a serine protease expressed at elevated levels in rosacea skin (compared to normal skin). It processes the precursor cathelicidin peptide into the active antimicrobial peptide LL-37.
In rosacea, this pathway is dysregulated:
Azelaic acid's mechanism in rosacea includes direct KLK5 inhibition — reducing LL-37 overproduction. This is the molecular basis for Finacea's clinical efficacy.
Vasodilation: Rosacea-prone skin shows increased expression of vascular endothelial growth factor (VEGF) and abnormal vascular reactivity — contributing to both persistent erythema and telangiectasia.
Transient receptor potential (TRP) channels: TRP channels (particularly TRPV1 and TRPA1) on sensory neurons and mast cells mediate the flushing response to heat, capsaicin, alcohol, and other triggers. Rosacea patients demonstrate heightened TRP channel sensitivity — the neurogenic flushing component.
Mast cell activation: Mast cells are significantly elevated in rosacea skin; they release histamine, prostaglandins, and VEGF in response to TRP channel activation and LL-37 → amplify vasodilation, flushing, and inflammation.
Rosacea triggers vary by individual but commonly include:
| Category | Common triggers |
|---|---|
| Environmental | Sun/UV exposure (most universal), wind, cold, heat |
| Dietary | Alcohol (especially red wine), hot beverages, spicy foods, histamine-rich foods (fermented foods, aged cheeses) |
| Physical | Exercise, hot baths/showers, saunas |
| Emotional | Stress, embarrassment, anxiety |
| Topical | Irritating skincare products (alcohol, fragrance, menthol, peppermint, eucalyptus, high-concentration AHAs) |
| Medications | Vasodilators (calcium channel blockers, ACE inhibitors, nitrates), niacin |
Trigger diary: Identifying personal triggers is one of the highest-yield interventions — rosacea is driven by cumulative trigger burden; eliminating 2–3 major triggers can dramatically reduce flare frequency even before starting medications.
Metronidazole 0.75% gel/cream (Metrogel, Noritate): First-line for papulopustular rosacea; anti-inflammatory mechanism (not primarily antibacterial as once thought); multiple RCTs demonstrate superiority over vehicle. FDA-approved.
Azelaic acid 15% gel (Finacea): FDA-approved for papulopustular rosacea; KLK5/ROS/free-radical scavenging mechanism; multiple pivotal RCTs; Thiboutot et al. 2003 (Arch Dermatol) demonstrated 58% vs. 40% vehicle success rate. Well-tolerated in sensitive rosacea skin.
Ivermectin 1% cream (Soolantra): FDA-approved for papulopustular rosacea; Demodex-targeting antiparasitic; Taieb et al. (2015, British Journal of Dermatology): Pivotal RCT demonstrating ivermectin 1% cream once daily significantly superior to metronidazole 0.75% BID at 16 weeks (IGA success: 84.9% vs. 75.4%); positioned as the most effective topical for PPR.
Brimonidine 0.33% gel (Mirvaso): Alpha-2 adrenergic receptor agonist — causes vasoconstriction of facial blood vessels → temporary reduction in erythema within 30 minutes; effect lasts 8–12 hours. Targets ETR erythema (not papules/pustules). Caveat: Rebound erythema on discontinuation is commonly reported — facial redness may rebound beyond baseline in some patients when the effect wears off.
Oxymetazoline 1% cream (Rhofade): Newer alpha-1A/alpha-2 adrenergic agonist; FDA-approved for persistent erythema; lower rebound erythema rate than brimonidine in clinical comparisons.
Doxycycline 40 mg modified-release (Oracea): Low-dose doxycycline at the sub-antimicrobial dose (40 mg MR QD) — operates via anti-inflammatory mechanisms (MMP inhibition, neutrophil function modulation) rather than antibiotic activity; minimizes antibiotic resistance risk. FDA-approved for rosacea; multiple RCTs confirm efficacy for PPR.
Standard doxycycline 50–100 mg: Used for moderate-to-severe PPR or ocular rosacea; antibiotic activity at this dose.
Isotretinoin (low-dose): 0.1–0.3 mg/kg/day in patients with severe or refractory rosacea, particularly phymatous subtype — reduces sebaceous gland activity and sebum production; anti-inflammatory. Off-label use.
Intense pulsed light (IPL): Targets oxyhemoglobin in dilated vessels — selectively destroys telangiectasia and reduces background erythema. Multiple studies support IPL as the most effective non-invasive treatment for ETR erythema and telangiectasia. Typically 3–5 sessions at 4-week intervals.
Pulsed dye laser (PDL, 595 nm): The most selective vascular laser; targets oxyhemoglobin with high selectivity → destroys telangiectasia; well-established for rosacea telangiectasia. The reference standard for individual telangiectasia treatment.
Nd:YAG laser (1064 nm): For deeper or resistant vessels; less precise than PDL but penetrates deeper; useful for larger caliber vessels.
Rosacea-prone skin requires a stripped-back, barrier-supportive routine:
Cleanser: Gentle, fragrance-free, no foaming SLS; lukewarm water (not hot)
Active ingredients to embrace:
Ingredients to avoid:
Looking for a rosacea treatment consultation? Browse med spa providers on MedSpot →